Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

18F F AraG - CellSight Technologies

Next Previous
Drug Profile

18F F AraG - CellSight Technologies

Alternative Names: 2'-deoxy-2'-[18F]fluoro-9-β-D-arabinofuranosylguanine; 18[F]F-AraG; 18F-AraG; [18F]F-ARAG PET; AraG-18[F]F; F18F-AraG; Flourine-18 labelled arabino furanosyl guanine - CellSight Technologies; Fluorine F 18 Ara-G; VisAcT

Latest Information Update: 20 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stanford University
  • Developer Boehringer Ingelheim; CellSight Technologies; Checkmate Pharmaceuticals; Stanford University; University of California at San Francisco; University of Pittsburgh
  • Class Arabinonucleosides; Furans; Imaging agents; Purines; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours
  • Phase I COVID 2019 infections
  • No development reported Bladder cancer; Cancer; Head and neck cancer; HIV infections

Most Recent Events

  • 13 Feb 2024 University of Pittsburgh, in collaboration with Checkmate Pharmaceuticals and CellSight Technologies suspends a phase II trial in Malignant melanoma (Late-stage disease, Combination therapy, Neoadjuvant therapy) in USA (IV) due to evaluation in process, and pending new trial with similar agents (NCT04401995)
  • 17 Jan 2024 CellSight Technologies terminates a phase I clinical trials in Non-small cell lung cancer (Diagnosis, Late-stage disease) in USA (IV) (NCT04524195)
  • 30 Oct 2023 CellSight Technologies plans a phase II trial for Non-small cell lung cancer (Diagnosis) (NCT06107374)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top